We are live on
!
Find out more
ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
1-Year Est. Return
44.72%
This Fund
S&P 500
This Quarter
Est. Return
+22.5%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$102M
AUM Growth
+$21.8M
(+27%)
Cap. Flow
+$7.13M
Cap. Flow
% of AUM
7.01%
Top 10 Holdings %
Top 10 Hldgs %
56.24%
Holding
49
New
13
Increased
10
Reduced
13
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$8.25M |
| 2 |
Acadia Healthcare
ACHC
|
+$5.17M |
| 3 |
AnaptysBio
ANAB
|
+$3.42M |
| 4 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$3.33M |
| 5 |
EXAS
Exact Sciences
EXAS
|
+$3.18M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PTC Therapeutics
PTCT
|
+$3.57M |
| 2 |
Natera
NTRA
|
+$2.51M |
| 3 |
KALA BIO
KALA
|
+$2.13M |
| 4 |
Syndax Pharmaceuticals
SNDX
|
+$1.94M |
| 5 |
Pfizer
PFE
|
+$1.89M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
OPTN
1
DELISTED
OptiNose
OPTN
| $9.4M | 9.24% |
22,388
-207
| -0.9% | -$69.8K |
|
|
2
Vertex Pharmaceuticals
VRTX
$123B
| $9.04M | 8.89% |
+53,208
| New | +$8.25M |
|
|
3
PTC Therapeutics
PTCT
$6.45B
| $6.92M | 6.8% |
205,031
-114,413
| -36% | -$3.57M |
|
|
4
Acadia Healthcare
ACHC
$3.13B
| $5.25M | 5.16% |
+128,240
| New | +$5.17M |
|
5
Jazz Pharmaceuticals
JAZZ
$15.5B
| $5.1M | 5.02% |
29,625
-1,679
| -5% | -$274K |
|
|
EXAS
6
DELISTED
Exact Sciences
EXAS
| $5.08M | 4.99% |
84,937
+59,134
| +229% | +$3.18M |
|
7
Centene
CNC
$32.8B
| $4.81M | 4.73% |
78,116
-18,436
| -19% | -$1.06M |
|
8
Insmed
INSM
$23.5B
| $4.7M | 4.62% |
198,801
+36,616
| +23% | +$942K |
|
9
UnitedHealth
UNH
$382B
| $3.55M | 3.49% |
14,452
-3,066
| -18% | -$736K |
|
|
AERI
10
DELISTED
Aerie Pharmaceuticals
AERI
| $3.36M | 3.3% |
49,756
-19,920
| -29% | -$1.11M |
|
|
PTLA
11
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $3.29M | 3.23% |
+87,116
| New | +$3.33M |
|
|
12
AnaptysBio
ANAB
$1.62B
| $2.89M | 2.84% |
+40,718
| New | +$3.42M |
|
|
VRAY
13
DELISTED
ViewRay, Inc.
VRAY
| $2.7M | 2.66% |
+390,568
| New | +$2.84M |
|
14
Quest Diagnostics
DGX
$23.2B
| $2.7M | 2.66% |
24,575
-7,654
| -24% | -$797K |
|
15
Neurocrine Biosciences
NBIX
$17.4B
| $2.64M | 2.6% |
26,910
-2,915
| -10% | -$261K |
|
16
Heron Therapeutics
HRTX
$88.7M
| $2.58M | 2.54% |
66,488
-10,858
| -14% | -$346K |
|
|
17
Natera
NTRA
$37.9B
| $2.24M | 2.2% |
118,869
-206,660
| -63% | -$2.51M |
|
|
GBT
18
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $2.23M | 2.19% |
49,355
+27,355
| +124% | +$1.25M |
|
|
ICPT
19
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $2.17M | 2.14% |
+25,918
| New | +$1.9M |
|
|
FOLD
20
DELISTED
Amicus Therapeutics
FOLD
| $2.06M | 2.03% |
132,160
-62,585
| -32% | -$946K |
|
21
Opko Health
OPK
$906M
| $1.91M | 1.88% |
406,526
+265,482
| +188% | +$1.01M |
|
22
Bio-Rad Laboratories Class A
BIO
$8.13B
| $1.71M | 1.68% |
5,918
+1,407
| +31% | +$388K |
|
23
Perrigo
PRGO
$1.45B
| $1.71M | 1.68% |
23,389
+10,642
| +83% | +$820K |
|
24
Sarepta Therapeutics
SRPT
$1.81B
| $1.49M | 1.46% |
11,249
-17,884
| -61% | -$1.69M |
|
25
Viking Therapeutics
VKTX
$4.31B
| $1.46M | 1.44% |
+154,207
| New | +$1.03M |
|
Similar funds
FAC
SWM
MC
KM
TI
GC
REMS
NM
Asymmetry Capital Management's Q2 2018 Portfolio in Review
As of Q2 2018, Asymmetry Capital Management held 49 positions worth $102M, up 27% from $79.9M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Asymmetry Capital Management deployed $7.13M of net new capital in Q2 2018, opening 13 new positions and adding to 10 existing holdings. Its largest new stake was Vertex Pharmaceuticals: 53,208 shares worth $9.04M.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 95% a quarter earlier.
On the sell side, the largest reduction was PTC Therapeutics, an estimated $3.57M trimmed.
- Asymmetry Capital Management's largest Q2 2018 buy was Vertex Pharmaceuticals: 53,208 shares worth $9.04M.
- Asymmetry Capital Management added most to Exact Sciences in Q2 2018, an estimated $3.18M increase.
- Asymmetry Capital Management's biggest Q2 2018 reduction was PTC Therapeutics, cutting an estimated $3.57M.
- Asymmetry Capital Management fully exited KALA BIO in Q2 2018, selling an estimated $2.13M.
- Asymmetry Capital Management's ten largest holdings make up 56% of its $102M portfolio in Q2 2018.
- Asymmetry Capital Management opened 13 new positions and closed 13 in Q2 2018.
- Asymmetry Capital Management's portfolio value rose 27% quarter-over-quarter to $102M.
Based on Asymmetry Capital Management's 13F filing for Q2 2018, filed 7 Aug 2018.